A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 100 (planned)
- Started
- Jun 6, 2023
- Main results expected
- Sep 30, 2026
- Fully finished
- Sep 30, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with Dose-Limiting Toxicities (DLTs)
Measured over: Up to approximately 4 years
Number of participants with Adverse Events (AEs)
Measured over: Up to approximately 4 years
Number of participants with Serious Adverse Events (SAEs)
Measured over: Up to approximately 4 years
Number of participants with AEs leading to discontinuation
Measured over: Up to approximately 4 years
Number of deaths
Measured over: Up to approximately 4 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05888831 · record last updated 2025-06-11 · checked 2026-11-09 15:47 UTC